State of the art in PEGylation: The great versatility achieved after forty years of research

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 461-472

  Pasut, Gianfranco ^a   Veronese, Francesco M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Drug delivery; PEG; PEGylation; Protein conjugation

Indexed keywords

AMINO GROUP; C-TERMINUS; CLINICAL PRACTICES; COMBINATION THERAPY; DISULPHIDE BRIDGE; GLYCANS; N-GLYCOSYLATION; PEGYLATION; PROTEIN PEGYLATION; PROTEIN SURFACE; PURIFICATION PROCESS; RANDOM COUPLINGS; REACTION CONDITIONS; REACTIVE GROUP; SINGLE-ISOMER; SITE SELECTIVE; STATE OF THE ART;

DRUG DELIVERY; GENETIC ENGINEERING; POLYETHYLENE GLYCOLS; PROTEINS;

AMINO ACIDS;

AMINO ACID; ASPARAGINASE MACROGOL; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYSTEINE; DRUG CARRIER; GLUTAMINE; GLYCAN; GLYCOPROTEIN; HISTIDINE; HYBRID PROTEIN; LYSINE; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGLOTICASE; PEGVISOMANT; POLYMER; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORTASE; THIOL;

ACROMEGALY; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONJUGATE; CONJUGATION; CROHN DISEASE; DRUG ACTIVITY; ELIMINATION REACTION; GENETIC ENGINEERING; GLYCOSYLATION; GOUT; HEPATITIS C; HUMAN; ISOMER; LACTONIZATION; LEUKEMIA; MEDICAL RESEARCH; NEUTROPENIA; NONHUMAN; PRESERVATION; PRIORITY JOURNAL; PURIFICATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; WET AGE RELATED MACULAR DEGENERATION;

ANIMALS; BIOMEDICAL RESEARCH; CHEMISTRY, PHARMACEUTICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 84861749627     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.10.037     Document Type: Review

References (139)

1. B. Leader, Q.J. Baca, D.E. Golan, Protein therapeutics: a summary and pharmacological classification, Nat. Rev. Drug Discovery 7 (2008) 21-39.
2. I. Kola, J. Landis, Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 3 (2004) 711-716.
3. K. Kimura, T. Taguchi, I. Urushizaki, R. Ohno, O. Abe, H. Furue, T. Hattori, H. Ichihashi, K. Inoguchi, H. Majima, Phase I study of recombinant human tumor necrosis factor, Cancer Chemother. Pharmacol. 20 (1987) 223-229.
4. S.A. Rosenberg, M.T. Lotze, L.M. Muul, A.E. Chang, F.P. Avis, S. Leitman, W.M. Linehan, C.N. Robertson, R.E. Lee, J.T. Rubin, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N. Engl. J. Med. 316 (1987) 889-897.
5. J.P. Leonard, M.L. Sherman, G.L. Fisher, L.J. Buchanan, G. Larsen, M.B. Atkins, J.A. Sosman, J.P. Dutcher, N.J. Vogelzang, J.L. Ryan, Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production, Blood 90 (1997) 2541-2548.
6. K. Petrak, P. Goddard, Transport of macromolecules across the capillary walls, Adv. Drug Delivery Rev. 3 (1989) 191-214.
7. D. Platis, N.E. Labrou, Chemical and genetic engineering strategies to improve the potency of pharmaceutical proteins and enzymes, Curr. Med. Chem. 15 (2008) 1940-1955.
8. L. Jorgensen, H.M. Nielson, Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines, John Wiley & Sons, Ltd., West Sussex (U.K, 2009.
9. P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N. Engl. J. Med. 342 (2000) 1171-1177.
10. J.A. Jazayeri, G.J. Carroll, Fc-based cytokines: prospects for engineering superior therapeutics, BioDrugs 22 (2008) 11-26.
11. S. Elliott, T. Lorenzini, S. Asher, Enhancement of therapeutic protein in vivo activities through glycoengineering, Nat. Biotechnol. 21 (2003) 414-421.
12. C. Pinto Reis, R.J. Neufeld, A.J. Ribeiro, F. Veiga, Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems, Nanomedicine 2 (2006) 53-65.
13. A.J. Almeida, E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and proteins, Adv. Drug Delivery Rev. 59 (2007) 478-490.
14. S. Martins, B. Sarmento, D.C. Ferreira, E.B. Souto, Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles, Int. J. Nanomed. 2 (2007) 595-607.
15. J.K. Tessmar, A.M. Göpferich, Matrices and scaffolds for protein delivery in tissue engineering, Adv. Drug Delivery Rev. 59 (2007) 274-291.
16. M.C. Jones, M. Patel, Insulin detemir: a long-acting insulin product, Am. J. Health Syst. Pharm. 63 (2006) 2466-2472.
17. F.M. Veronese, G. Pasut, PEGylation: posttranslational bioengineering of protein biotherapeutics, Drug Discov. Today Technol. 5 (2008) e57-e64.
18. K.Maggon, R&D paradigmshift and billion-dollar biologics, in: S.C. Gad (Ed.), Handbook of Pharmaceutical and Biotechnology, Wiley, New York, 2007, pp. 161-198.
19. P. Bailon, C.Y. Won, PEG-modified biopharmaceuticals, Expert Opin. Drug Deliv. 6 (2009) 1-16.
20. S.M. Ryan, G. Mantovani, X. Wang, D.M. Haddleton, D.J. Brayden, Advances in PEGylation of important biotech molecules: delivery aspects, Expert Opin. Drug Deliv. 5 (2008) 371-383.
21. G. Pasut, F.M. Veronese, PEG conjugates in clinical development or use as anticancer agents: an overview, Adv. Drug Deliv. Rev. 61 (2009) 1177-1188.
22. G. Pasut, M. Sergi, F.M. Veronese, Anti-cancer PEG-enzymes: 30 years old, but still a current approach, Adv. Drug Deliv. Rev. 60 (2008) 69-78.
23. A. Basu, K. Yang, M. Wang, S. Liu, R. Chintala, T. Palm, H. Zhao, P. Peng, D. Wu, Z. Zhang, J. Hua, M.C. Hsieh, J. Zhou, G. Petti, X. Li, A. Janjua, M. Mendez, J. Liu, C. Longley, Z. Zhang, M. Mehlig, V. Borowski, M. Viswanathan, D. Filpula, Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation, Bioconjug. Chem. 17 (2006) 618-630.
24. K. Hinds, J.J. Koh, L. Joss, F. Liu, M. Baudys, S.W. Kim, Synthesis and characterization of poly(ethylene glycol)-insulin conjugates, Bioconjug. Chem. 11 (2) (2000) 195-201.
25. C. Dhalluin, A. Ross, L.A. Leuthold, S. Foser, B. Gsell, F. Müller, H. Senn, Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers, Bioconjug. Chem. 16 (3) (2005) 504-517.
26. G. Digilio, L. Barbero, C. Bracco, D. Corpillo, P. Esposito, G. Piquet, S. Traversa, S. Aime, NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2, J. Am. Chem. Soc. 125 (2003) 3458-3470.
27. K.D. Hinds, S.W. Kim, Effects of PEG conjugation on insulin properties, Adv. Drug Deliv. Rev. 54 (2002) 505-530.
28. F. Meng, B.N. Manjula, P.K. Smith, S.A. Acharya, PEGylation of human serum albumin: reaction of PEG-phenyl-isothiocyanate with protein, Bioconjug. Chem. 19 (2008) 1352-1360.
29. F.M. Veronese, A. Mero, F. Caboi, M. Sergi, C. Marongiu, G. Pasut, Site-specific pegylation of G-CSF by reversible denaturation, Bioconjug. Chem. 18 (2007) 1824-1830.
30. J.M. Harris, R.B. Chess, Effect of PEGylation on pharmaceuticals, Nat. Rev. Drug Discov. 2 (2003) 214-221.
31. J. Israelachvili, The different faces of poly(ethylene glycol), Proc. Natl. Acad. Sci. 94 (1997) 8378-8379.
32. J. Klein, P.F. Luckham, Variation of effective adsorbed polymer layer thickness with molecular weight in good and poor solvents, Macromolecules 19 (1986) 2007-2010.
33. P.F. Luckham, J. Klein, Interactions between smooth solid surfaces in solutions of adsorbing and nonadsorbing polymers in good solvent conditions, Macromolecules 18 (1985) 721-728.
34. T.L. Kuhl, D.E. Leckband, D.D. Lasic, J.N. Israelachvili, Modulation of interaction forces between lipid bilayers exposing short chained ethylene oxide, Biophys. J. 66 (1994) 1479-1488.
35. L.T. Boni, T.P. Stewart, J.L. Alderfer, S.W. Hui, Lipid-polyethylene glycol interactions: II. Formation of defects in bilayers, J. Membr. Biol. 62 (1981) 65-70.
36. L.T. Boni, T.P. Stewart, J.L. Alderfer, S.W. Hui, Alterations in phospholipid polymorphism by polyethylene glycol, J. Membr. Biol. 80 (1984) 91-104.
37. L.A.M. Rupert, J.B.F.N. Engberts, D. Hoekstra, Effect of poly(ethylene glycol) on the calcium-induced fusion of didodecyl phosphate vesicles, Biochemistry 27 (1988) 8232-8239.
38. T.L. Kuhl, Y. Guo, J.L. Alderfer, A. Berman, D.E. Leckband, J. Israelachvili, S.W. Hui, Direct measurement of polyethylene glycol induced depletion attraction between lipid bilayers, Langmuir 12 (1996) 3003-3014.
39. J.M. Harris, Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, Plenum Press, New York, 1991.
40. C.J. Fee, J.M. Van Alstine, Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins, Bioconjug. Chem. 15 (2004) 1304-1313.
41. T. Yamaoka, Y. Tabata, Y. Ikada, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice, J. Pharm. Sci. 83 (1994) 601-606.
42. T. Yamaoka, Y. Tabata, Y. Ikada, Fate of water-soluble administered via different routes, J. Pharm. Sci. 84 (1995) 349-354.
43. C. Fruijtier-Polloth, Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products, Toxicology 214 (2005) 1-38.
44. A. Bendele, J. Seely, C. Richey, G. Sennello, G. Shopp, Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins, Toxicol. Sci. 42 (1998) 152-157.
45. M.A. Young, A. Malavalli, N. Winslow, K.D. Vandegriff, R.M. Winslow, Toxicity and hemodnamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys, Toxicol. Sci. 149 (2007) 333-342.
46. K.L. Shum, A. Leon, A.T. Viau, D. Pilon, M. Nucci, R.G. Shorr, The physiological and histopathological response of dogs to exchange transfusion with polyethylene glycol-modified bovine hemoglobin (PEG-Hb), Artif. Cells, Blood Substitues, Immobilization Biotechnol. 24 (1996) 655-683.
47. C. Conover, L. Lejunne, R. Linberg, K. Shum, R.G. Shorr, Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat, Artif. Cells, Blood Substitues, Immobilization Biotechnol. 24 (1996) 599-611.
48. M.J. Roberts, M.D. Bentley, J.M. Harris, Chemistry for peptide and protein PEGylation, Adv. Drug Deliv. Rev. 54 (2002) 459-476.
49. G. Pasut, F. Caboi, R. Schrepfer, G. Tonon, O. Schiavon, F.M. Veronese, New active poly(ethylene glycol) derivative for amino coupling, React. Funct. Polym. 67 (2007) 529-539.
50. C. Monfardini, O. Schiavon, P. Caliceti, M. Morpurgo, J.M. Harris, F.M. Veronese, A branched monomethoxypoly(ethylene glycol) for protein modification, Bioconjug Chem. 6 (1995) 62-69.
51. F.M. Veronese, J.M. Harris, Introduction and overview of peptide and protein PEGylation, theme issue on PEGylation, Adv. Drug Deliv. Rev. 54 (4) (2002).
52. J.M. Harris, F.M. Veronese, Peptide and protein PEGylation II - clinical evaluation, theme issue on PEGylation, Adv. Drug Deliv. Rev. 55 (10) (2003).
53. F.M. Veronese, J.M. Harris, Peptide and protein Pegylation III: advances in chemistry and clinical applications, theme issue on PEGylation, Adv. Drug Deliv. Rev. 60 (1) (2008).
54. F.M. Veronese, PEGylated Protein Drugs: Basic Science and Clinical Applications, Birkhäuser Verlag, Basel (CH), 2009.
55. S.S. Wong, Reactive groups of proteins and their modifying agents, in: S.S. Wong (Ed.), Chemistry of Protein Conjugation and Cross-linking, CRC Press, Boston, 1991, p. 13.
56. O.B. Kinstler, D.N. Brems, L.S. Lauren, A.G. Paige, J.B. Hamburger, M.J. Treuheit, Characterization and stability of N-terminally pegylated rhG-CSF, Pharm. Res. 13 (1995) 996-1002.
57. J. Hu, W. Sebald, N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH, Int. J. Pharm. 413 (2011) 140-146.
58. J. Wang, T. Hu, Y. Liu, G. Zhang, G. Ma, Z. Su, Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase, Anal. Biochem. 412 (2011) 114-116.
59. T. Arakawa, S.J. Prestrelski, L.O. Narhi, T.C. Boone, W.C. Kenney, Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed, J. Protein Chem. 12 (1993) 525-531.
60. A.M. Nesbitt, S. Stephens, E.K. Chartash, Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent, in: F.M. Veronese (Ed.), PEGylated Protein Drugs: Basic Science and Clinical Applications, Birkhäuser Verlag, Basel, Switzerland, 2009, pp. 229-254.
61. S.C. Alley, D.R. Benjamin, S.C. Jeffrey, N.M. Okeley, D.L. Meyer, R.J. Sanderson, P.D. Senter, Contribution of linker stability to the activities of anticancer immunoconjugates, Bioconjug. Chem. 19 (2008) 759-765.
62. A.D. Baldwin, K.L. Kiick, Tunable degradation of maleimide-thiol adducts in reducing environments, Bioconjug. Chem. 22 (2011) 1946-1953.
63. G. Saito, J.A. Swanson, K. Lee, Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities, Adv. Drug Deliv. Rev. 55 (2003) 199-215.
64. A.P. Chapman, PEGylated antibodies and antibody fragments for improved therapy: a review, Adv. Drug. Deliv. Rev. 54 (2002) 531-545.
65. S. Shaunak, A. Godwin, J.W. Choi, S. Balan, E. Pedone, D. Vijayarangam, S. Heidelberger, I. Teo, M. Zloh, S. Brocchini, Site-specific PEGylation of native disulfide bonds in therapeutic proteins, Nat. Chem. Biol. 2 (2006) 312-313.
66. S. Balan, J.W. Choi, A. Godwin, I. Teo, C.M. Laborde, S. Heidelberger, M. Zloh, S. Shaunak, S. Brocchini, Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge, Bioconjug. Chem. 18 (2007) 61-76.
67. S. Brocchini, A. Godwin, S. Balan, J.W. Choi, M. Zloh, S. Shaunak, Disulfide bridge based PEGylation of proteins, Adv. Drug Deliv. Rev. 60 (2008) 3-12.
68. F.F. Schumacher, M. Nobles, C.P. Ryan, M.E. Smith, A. Tinker, S. Caddick, J.R. Baker, In situ maleimide bridging of disulfides and a new approach to protein PEGylation, Bioconjug. Chem. 22 (2) (2011) 132-136.
69. V.W. Cornish, K.M. Hahn, P.G. Schultz, Site-specific protein modification using a ketone handle, J. Am. Chem. Soc. 118 (1996) 8150-8151.
70. L. Wang, A. Brock, B. Herberich, P.G. Schultz, Expanding the genetic code of Escherichia coli, Science 292 (2001) 498-500.
71. H. Cho, T. Daniel, Y.J. Buechler, D.C. Litzinger, Z. Maio, A.M. Putnam, V.S. Kraynov, B.C. Sim, S. Bussell, T. Javahishvili, S. Kaphle, G. Viramontes, M. Ong, S. Chu, G.C. Becky, R. Lieu, N. Knudsen, P. Castiglioni, T.C. Norman, D.W. Axelrod, A.R. Hoffman, P.G. Schultz, R.D. DiMarchi, B.E. Kimmel, Optimized clinical performance of growth hormone with an expanded genetic code, Proc. Natl. Acad. Sci. U. S. A. 108 (22) (2011) 9060-9065.
72. A. Deiters, T.A. Cropp, D. Summerer, M. Mukherji, P.G. Schultz, Site-specific PEGylation of proteins containing unnatural amino acids, Bioorg. Med. Chem. Lett. 14 (2004) 5743-5745.
73. G. Srinivasan, C.M. James, J.A. Krzycki, Pyrrolysine encoded by UAG in Archaea: charging of a UAG-decoding specialized tRNA, Science 296 (2002) 1459-1462.
74. Y. Zhang, P.V. Baranov, J.F. Atkins, V.N. Gladyshev, Pyrrolysine and selenocysteine use dissimilar decoding strategies, J. Biol. Chem. 280 (2005) 20740-20751.
75. D.G. Longstaff, R.C. Larue, J.E. Faust, A. Mahapatra, L. Zhang, K.B. Green-Church, J.A. Krzycki, A natural genetic code expansion cassette enables transmissible biosynthesis and genetic encoding of pyrrolysine, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1021-1026.
76. S.E. Cellitti, W. Ou, H. Chiu, J. Grünewald, D.H. Jones, X. Hao, Q. Fan, L.L. Quinn, K. Ng, A.T. Anfora, S.A. Lesley, T. Uno, A. Brock, B.H. Geierstanger, D-ornithine coopts pyrrolysine biosynthesis to make and insert pyrroline-carboxy-lysine, Nat. Chem. Biol. 7 (2011) 528-530.
77. W. Ou, T. Uno, H.P. Chiu, J. Grünewald, S.E. Cellitti, T. Crossgrove, X. Hao, Q. Fan, L.L. Quinn, P. Patterson, L. Okach, D.H. Jones, S.A. Lesley, A. Brock, B.H. Geierstanger, Site-specific protein modifications through pyrroline-carboxy-lysine residues, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 10437-10442.
78. N.M. Nairn, T.J. Graddis, A. Wang, K. Shanebeck, K. Grabstein, Site-specific PEGylation of interferon-beta by Cu(I)-catalyzed cycloaddition, 234th American Chemical Society National Meeting, 2007, Boston MA, 2007.
79. J. Thom, D. Anderson, J. McGregor, G. Cotton, Recombinant protein hydrazides: application to site-specific protein PEGylation, Bioconjug. Chem. 22 (2011) 1017-1020.
80. C.S. Greenberg, P.J. Birckbichler, R.H. Rice, Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues, FASEB J. 5 (1991) 3071-3077.
81. H. Sato, Enzymatic procedure for site-specific pegylation of proteins, Adv. Drug Deliv. Rev. 54 (2004) 487-504.
82. A. Fontana, B. Spolaore, A. Mero, F.M. Veronese, Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase, Adv. Drug. Deliv. Rev. 60 (2008) 13-28.
83. A. Mero, M. Schiavon, F.M. Veronese, G. Pasut, A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone, J. Control. Release 154 (2011) 27-34.
84. S. DeFrees, Z. Wang, R. Xing, A.E. Scott, J. Wang, D. Zopf, D.L. Gouty, E.R. Sjoberg, K. Panneerselvam, E.C.M. Brinkman-Van der Linden, A.R. Bayer, M.A. Tarp, H. Clausen, GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli, Glycobiology 16 (2006) 833-843.
85. H.R. Stennicke, H. Ostergaard, R.J. Bayer, M.S. Kalo, K. Kinealy, P.K. Holm, B.B. Sørensen, D. Zopf, S.E. Bjørn, Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives, Thromb. Haemost. 100 (5) (2008) 920-928.
86. H. Ostergaard, J.R. Bjelke, L. Hansen, L.C. Petersen, A.A. Pedersen, T. Elm, F. Møller, M.B. Hermit, P.K. Holm, T.N. Krogh, J.M. Petersen, M. Ezban, B.B. Sørensen, M.D. Andersen, H. Agersø, H. Ahmadian, K.W. Balling, M.L. Christiansen, K. Knobe, T.C. Nichols, S.E. Bjørn, M. Tranholm, Prolonged half-life and pre-served enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide, Blood 118 (8) (2011) 2333-2341.
87. C. Negrier, K. Knobe, A. Tiede, P. Giangrande, J. Møss, Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with haemophilia B, Blood 118 (10) (2011) 2695-2701.
88. L.A. Marraffini, A.C. Dedent, O. Schneewind, Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria, Microbiol. Mol. Biol. Rev. 70 (2006) 192-221.
89. H. Ton-That, G. Liu, S.K. Mazmanian, K.F. Faull, O. Schneewind, Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12424-128429.
90. M.W. Popp, J.M. Antos, G.M. Grotenbreg, E. Spooner, H.L. Ploegh, Sortagging: a versatile method for protein labeling, Nat. Chem. Biol. 3 (2007) 707-708.
91. T. Tanaka, T. Yamamoto, S. Tsukiji, T. Nagamune, Site-specific protein modification on living cells catalyzed by Sortase, ChemBioChem 9 (2008) 802-807.
92. M.W. Popp, S.K. Dougan, T.Y. Chuang, E. Spooner, H.L. Ploegh, Sortase-catalyzed transformations that improve the properties of cytokines, Proc. Natl. Acad. Sci. U. S. A. 108 (8) (2011) 3169-3174.
93. Peginterferon Alfa-2b Product Information. Kenilworth, NJ, USA: Schering Corporation.
94. H. Zhao, K. Yang, A. Martinez, A. Basu, R. Chintala, H.C. Liu, A. Janjua, M. Wang, D. Filpula, Linear and branched bicin linkers for releasable PEGylation of macro-molecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins, Bioconjug. Chem. 17 (2006) 341-351.
95. R.B. Greenwald, K. Yang, H. Zhao, C.D. Conover, S. Lee, D. Filpula, Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery system employing 1,6-elimination, Bioconjug. Chem. 14 (2003) 395-403.
96. R.B. Greenwald, Y.H. Choe, C.D. Conover, K. Shum, D. Wu, M. Royzen, Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds, J. Med. Chem. 43 (2000) 475-487.
97. H. Tsubery, M. Mironchik, M. Fridkin, Y. Shechter, Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification, J. Biol. Chem. 279 (2004) 38118-38122.
98. Y.S. Wang, S. Youngster, M. Grace, J. Bausch, R. Bordens, D.F. Wyss, Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications, Adv. Drug Deliv. Rev. 54 (2002) 547-570.
99. D.C. Wylie, M. Voloch, S. Lee, Y.H. Liu, S. Cannon-Carlson, C. Cutler, B. Pramanik, Carboxyalkylated histidine is a pH-dependent product of pegylation with SCPEG, Pharm. Res. 18 (2001) 1354-1360.
100. Y.S. Wang, S. Youngster, J. Bausch, R. Zhang, C. Mcnemar, D.F. Wyss, Identification of the major positional isomer of pegylated interferon alpha-2b, Biochemistry 39 (2000) 10634-10640.
101. G. Pasut, A. Mero, F. Caboi, S. Scaramuzza, L. Sollai, F.M. Veronese, A new PEGbeta-alanine active derivative for releasable protein conjugation, Bioconjug. Chem. 19 (12) (2008) 2427-2431.
102. C. Mueller, M.A. Capelle, T. Arvinte, E. Seyrek, G. Borchard, Noncovalent pegylation by dansyl-poly(ethylene glycol)s as a new means against aggregation of salmon calcitonin, J. Pharm. Sci. 100 (5) (2011) 1648-1662.
103. C. Mueller, M.A. Capelle, T. Arvinte, E. Seyrek, G. Borchard, Tryptophan-mPEGs: novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation, Eur. J. Pharm. Biopharm. 79 (3) (2011) 646-657.
104. A. Mero, T. Ishino, I. Chaiken, F.M. Veronese, G. Pasut, Multivalent and Flexible PEG-Nitrilotriacetic Acid Derivatives for Non-covalent Protein Pegylation, Pharm. Res. 28 (10) (2011) 2412-2421.
105. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release 65 (2000) 271-284.
106. Y.H. Choe, C.D. Conover, D. Wu, M. Royzen, Y. Gervacio, V. Borowski, M. Mehlig, R.B. Greenwald, Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors, J. Control. Release 79 (2002) 55-70.
107. O. Schiavon, G. Pasut, S. Moro, P. Orsolini, A. Guiotto, F.M. Veronese, PEG-Ara-C conjugates for controlled release, Eur. J. Med. Chem. 39 (2004) 123-133.
108. G. Pasut, S. Scaramuzza, O. Schiavon, R. Mendichi, F.M. Veronese, PEG-epirubicin conjugates with high loading, J. Bioact. Compat. Polym. 20 (2005) 213-230.
109. G. Pasut, F. Canal, L. Dalla Via, S. Arpicco, F.M. Veronese, O. Schiavon, Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid, J. Control. Release 127 (2008) 239-248.
110. F.M. Veronese, O. Schiavon, G. Pasut, R. Mendichi, L. Andersson, A. Tsirk, J. Ford, G. Wu, S. Kneller, J. Davies, R. Duncan, PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity, Bioconjug. Chem. 16 (2005) 775-784.
111. L. Andersson, J. Davies, R. Duncan, P. Ferruti, J. Ford, S. Kneller, R. Mendichi, G. Pasut, O. Schiavon, C. Summerford, A. Tirk, F.M. Veronese, V. Vincenzi, G. Wu, Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEGpeptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates, Biomacromol 6 (2005) 914-926.
112. T.M. Allen, Ligand-targeted therapeutics in anticancer therapy, Nat. Rev. Cancer 2 (2002) 750-763.
113. C. Clementi, K. Miller, A. Mero, R. Satchi-Fainaro, G. Pasut, Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms, Mol. Pharm. 8 (4) (2011) 1063-1072.
114. S. Salmaso, A. Semenzato, P. Caliceti, J. Hoebeke, F. Sonvico, C. Dubernet, P. Couvreur, Specific antitumor targetable beta-cyclodextrin- poly(ethylene glycol)-folic acid drug delivery bioconjugate, Bioconjug. Chem. 15 (2004) 997-1004.
115. S. Jayant, J.J. Khandare, Y. Wang, A.P. Singh, N. Vorsa, T. Minko, Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment, Pharm. Res. 24 (11) (2007) 2120-2130.
116. S.S. Dharap, B. Qiu, G.C. Williams, P. Sinko, S. Stein, T. Minko, Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides, J. Control. Release 91 (2003) 61-73.
117. F. Canal, M.J. Vicent, G. Pasut, O. Schiavon, Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates, J. Control. Release 146 (3) (2010) 388-399.
118. G. Pasut, F. Greco, A. Mero, R. Mendichi, C. Fante, R.J.Green, F.M. Veronese, Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action, J. Med. Chem. 52 (2009) 6499-6502.
119. F. Greco, M.J. Vicent, Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines, Adv. Drug Deliv. Rev. 61 (2009) 1203-1213.
120. L. Santucci, A. Mencarelli, B. Renga, G. Pasut, F. Veronese, A. Zacheo, A. Germani, S. Fiorucci, Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin, FASEB J. 20 (2006) 765-767.
121. L. Santucci, A. Mencarelli, B. Renga, D. Ceccobelli, G. Pasut, F.M. Veronese, E. Distrutti, S. Fiorucci, Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin inmice, Anticancer Drugs 18 (2007) 1081-1091.
122. G. Pasut, F.M. Veronese, Polymer-drug conjugation, recent achievements and general strategies, Prog. Polym. Sci. 32 (2007) 933-961.
123. A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, F.F. Davis, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase, J. Biol. Chem. 252 (1977) 3582-3586.
124. A. Abuchowski, T. van Es, N.C. Palczuk, F.F. Davis, Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol, J. Biol. Chem. 252 (1997) 3578-3581.
125. P. Caliceti, F.M. Veronese, Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates, Adv. Drug Deliv. Rev. 55 (2003) 1261-1277.
126. G. Pasut, F.M. Veronese, PEGylation for improving the effectiveness of therapeutic biomolecules, Drugs Today (Barc) 45 (9) (2009) 687-695.
127. F. Metzger, W. Sajid, S. Saenger, C. Staudenmaier, C. van der Poel, B. Sobottka, A. Schuler, M. Sawitzky, R. Poirier, D. Tuerck, E. Schick, A. Schaubmar, F. Hesse, K. Amrein, H. Loetscher, G.S. Lynch, A. Hoeflich, P. De Meyts, H.J. Schoenfeld, Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I), J. Biol. Chem. 286 (2011) 19501-19510.
128. E.W.M. Ng, D.T. Shima, P. Calias, E.T. Cunningham, D.R. Guyer Jr., A.P. Adamis, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat. Rev. Drug Discov. 5 (2006) 123-132.
129. M. D'Este, G. Pasut, D. Renier, A. Rosato, Process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules, polymeric conjugates and relative uses thereof. 2010, WO 2010145821
130. A. Besheer, T.C. Hertel, J. Kressler, K. Mäder, M. Pietzsch, Enzymatically catalyzed HES conjugation using microbial transglutaminase: proof of feasibility, J. Pharm. Sci. 98 (11) (2009) 4420-4428.
131. A. Mero, G. Pasut, L. Dalla Via, M.W. Fijten, U.S. Schubert, R. Hoogenboom, F.M. Veronese, Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates? J. Control. Release 125 (2008) 87-95.
132. T.X. Viegas, M.D. Bentley, J.M. Harris, Z. Fang, K. Yoon, B. Dizman, R. Weimer, A. Mero, G. Pasut, F.M. Veronese, Polyoxazoline: chemistry, properties, and applications in drug delivery, Bioconjug. Chem. 22 (2011) 976-986.
133. G. Gregoriadis, S. Jain, I. Papaioannou, P. Laing, Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids, Int. J. Pharm. 300 (2005) 125-130.
134. Y. Levy, M.S. Hershfield, C. Fernandez-Mejia, S.H. Polmar, D. Scrudiery, M. Berger, R.U. Sorensen, Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with polyethylene glycol modified adenosine deaminase, J. Pediatr. 113 (1988) 312-317.
135. L.M. Graham, PEGASPARAGINASE: a review of clinical studies, Adv. Drug Deliv. Rev. 10 (2003) 1293-1302.
136. K.R. Reddy, M.W. Modi, S. Pedder, Use of peginterferon α2a (40KD) (Pegasys®) for the treatment of hepatitis C, Adv. Drug Deliv. Rev. 54 (2002) 571-586.
137. O. Kinstler, G. Moulinex, M. Treheit, D. Ladd, C. Gegg, Mono-N-terminal poly(ethylene glycol)-protein conjugates, Adv. Drug Deliv. Rev. 54 (2002) 477-485.
138. I.C. Macdougall, CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia, Curr. Hematol. Rep. 4 (6) (2005) 436-440.
139. M.R. Sherman, M.G. Saifer, F. Perez-Ruiz, PEG-uricase in the management of treatment-resistant gout and hyperuricemia, Adv. Drug Deliv. Rev. 60 (2008) 59-68.